| Popis: |
To compare the efficacy and tolerability of heme-iron Optifer (HIO) versus intravenous (IV) iron saccharate/Ferosac in treatment of iron deficiency anemia (IDA) during pregnancy. Two hundred and thirty-six (236) women with moderate IDA (hemoglobin > 7 and < 10 gm/dl) were included in this comparative multicenter study: 117 women in HIO/Optifer group and 119 women in IV/Ferosac group. Women in HIO/Optifer group received Optifer tablets twice daily till hemoglobin level of 11–12 gm/dl then once daily (maintenance dose). Total IV iron dose calculated for the studied women in the IV/Ferosac group according to the manufacturer instructions. The pre-treatment ferritin, hemoglobin (Hb), RBCs-mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH) were compared by post-treatment values in the two studied groups. The mean post-treatment Hb and ferritin were similar with no significant difference between HIO/Optifer group and IV/Ferosac group (11.7 ± 5.5 gm/dl and 118.8 ± 66.9 μg/l, respectively, versus 12.4 ± 6.1 and 132.9 ± 75.3, respectively), (P = 0.87 and 0.89, respectively). The mean post-treatment MCV and MCH were similar with no significant difference between HIO/Optifer group and IV/Ferosac group (94.0 ± 7.2 fl and 29.4 ± 2.9 pg, respectively, versus 97.7 ± 6.6 and 31.7 ± 4.2, respectively), (P = 0.17 and 0.99, respectively). The HIO/Optifer is an effective, well tolerable oral iron for treatment of moderate IDA during pregnancy with similar efficacy to IV iron saccharate/Ferosac. The IV iron saccharate/Ferosac is safe and an effective alternative to heme-iron for treatment of moderate IDA in women presented with IDA at later gestation when rapid replacement of iron stores required. |
Full text from SpringerLink